Max Lugavere: First Alzheimer’s Creatine Trial Shows Shocking Results! | TUH #178

Max Lugavere unpacks the rationale: Alzheimer’s involves a stark inability of the brain to produce ATP from glucose. Creatine, as a component of the phosphocreatine system, buffers and recycles ATP, and in theory can mitigate bioenergetic failure. The trial put this idea to the test with 20 patients, showing that a high oral dose could improve cognitive scores. Lugavere contrasts this metabolic approach with the amyloid-targeting drugs that carry risks of brain swelling and haemorrhage. He acknowledges the limitations—no placebo group, small sample—but frames the study as proof-of-concept that something as cheap and safe as creatine might become part of Alzheimer’s care, particularly when combined with prevention-focused lifestyle changes.

Gary Brecka states that women avoid creatine because it’s ‘widely thought of as the bodybuilding supplement’. He believes there are biochemical reasons—cognitive, hormonal—why women over 40 benefit from consistent supplementation. While he provides no detailed mechanism, his remark sits within the larger conversation about creatine’s brain benefits and the new trial data. It underscores a public-health message: a substance often dismissed can serve broader demographic needs.

Max Lugavere describes the trial’s design: single-arm, no placebo group, 20 patients, 8 weeks, 20g of creatine daily. He points out that this dose is about four times a typical loading dose and well above the 3–5g used for muscle saturation. The high dose is necessary because muscles preferentially soak up dietary creatine; brain creatine levels do not differ between vegans and omnivores, suggesting dietary intake doesn’t modulate brain levels. The trial demonstrated significant gains across cognitive scores, supporting the hypothesis that supra-physiological creatine pushes into the brain. Lugavere sees this as targeting the root cause—impaired brain energy production—rather than downstream amyloid plaques, which he calls a consequence, not the genesis of the disease. He stresses that while this pilot is small and lacked a placebo, it opens the door for larger studies and validates creatine as a safe, low-risk option.

Lugavere explains that while 3–5 grams per day saturates muscles after about 28 days, achieving muscle saturation does not guarantee brain delivery. The body appears to prioritise muscle uptake, leaving the brain ‘under the radar’ at dietary or low-supplement doses. Because brain levels are not modulated by diet, one needs a much higher oral dose—like the 20g used in the trial—to push creatine past the muscle sink and into the central nervous system. This finding rationalises the hefty dose in the Alzheimer’s pilot and could influence recommendations for mental performance, ageing, and sleep-deprivation mitigation.